Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Pass Above Fifty Day Moving Average – Should You Sell?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $20.28 and traded as high as $22.2775. Hikma Pharmaceuticals shares last traded at $22.2775, with a volume of 200 shares traded.

Wall Street Analyst Weigh In

Separately, Citigroup assumed coverage on Hikma Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Hikma Pharmaceuticals has a consensus rating of “Hold”.

Hikma Pharmaceuticals Stock Up 3.3%

The company’s fifty day simple moving average is $20.28 and its two-hundred day simple moving average is $19.47. The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.